One year results of anti-VEGF treatment in pigment epithelial detachment secondary to macular degeneration

Basit Öğe Kaydı
dc.contributor.authorYuksel, Harun
dc.contributor.authorTurkcu, Fatih M.
dc.contributor.authorSahin, Alparslan
dc.contributor.authorSahin, Muhammed
dc.contributor.authorCinar, Yasin
dc.contributor.authorCingu, Abdullah K.
dc.contributor.authorAri, Seyhmus
dc.date.accessioned2024-04-24T17:37:43Z
dc.date.available2024-04-24T17:37:43Z
dc.date.issued2013
dc.departmentDicle Üniversitesien_US
dc.description.abstractPurpose: Pigment epithelial detachment (PED) may be seen in all stages of age-related macular degeneration (ARMD) and may lead to poor prognosis. In this study, we retrospectively examined the effect of anti-VEGF treatments in ARMD patients with vascularized PED. Methods: Medical records of 15 patients with PED secondary to ARMD were re--viewed retrospectively. The diagnosis of PED was made with fundoscopy, fundus fluorescein angiography and optical coherence tomography. Patients were treated with intravitreal ranibizumab or/and bevacizumab and followed up for a minimum of one year. PED height and best corrected visual acuity (BCVA) was obtained before the first intravitreal anti-VEGF injection and again at the 1st, 3rd, 6th and 12th month after the injection. Results: The mean baseline BCVA was 0.71 +/- 0.48 logarithm of the minimal angle of resolution (logMAR) unit and the mean baseline PED height was 361 +/- 153 mu. The mean injection count per eye was 3.9 +/- 2.9. There was a significant reduce in mean PED height (247 +/- 177 mu) also in 2 eyes PED completely resolved at the end of the follow up period. The mean BCVA at 12th month (0,69 +/- 0,37) were not different from the baseline record. Conclusions: This retrospective case series showed that intravitreal anti-VEGF therapy preserved vision and reduced PED height in PED patients in a one-year follow-up period.en_US
dc.identifier.endpage211en_US
dc.identifier.issn0004-2749
dc.identifier.issue4en_US
dc.identifier.pmid24061828
dc.identifier.scopus2-s2.0-84886377070
dc.identifier.scopusqualityQ3
dc.identifier.startpage209en_US
dc.identifier.urihttps://hdl.handle.net/11468/21139
dc.identifier.volume76en_US
dc.identifier.wosWOS:000324914800002
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherConsel Brasil Oftalmologiaen_US
dc.relation.ispartofArquivos Brasileiros De Oftalmologia
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectVascular Endothelial Growth Factor A/Antagonists & Inhibitorsen_US
dc.subjectRetinal Pigment Epithelium/Pathologyen_US
dc.subjectRetinal Detachmenten_US
dc.subjectMacular Degeneration/Drug Therapyen_US
dc.subjectAgeden_US
dc.titleOne year results of anti-VEGF treatment in pigment epithelial detachment secondary to macular degenerationen_US
dc.titleOne year results of anti-VEGF treatment in pigment epithelial detachment secondary to macular degeneration
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu